Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer

H. Gunqor, Hani Gabra(Royal Children's Hospital), Roshan Agarwal(Imperial College Healthcare NHS Trust), Sarah P. Blagden(Churchill Hospital), Euan A. Stronach(Age UK), Afnan Saleem, GB Mills, Shannon R. Morris(Research Triangle Park Foundation), Syed Babar, Edward Curry(Age UK)
European Journal of Cancer
September 1, 2011
10.1016/s0959-8049(11)70123-x
Cited by 1

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
|Nature|2019|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222